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The purpose of this study is to investigate the associations of microvessel density (MVD) and other pathological variables with
survival, and whether they accounted for survival differences between Japanese and British patients. One hundred seventy-three
Japanese and 184 British patients were included in the study. British patients were significantly older (56.3±11.4 years vs 52.5±12.9
years; Po0.01) and had smaller tumours (2.2±1.3 vs 2.7±1.8cm; Po0.01), which were more frequently oestrogen receptor
positive (78.8 vs 57.2%, Po0.01), had more grade III tumours (29.9 vs 21.4%, P¼0.04) and more infiltrating lobular carcinomas (13.6
vs 4.0%, Po0.01) and a higher MVD compared with Japanese patients (57.9±19.8 vs 53.2±18.6; P¼0.01). However, no difference
in the prevalence of lymph-node metastasis was found between them (39.1 vs 37.5%, P¼0.75). Younger British patients (age o50
years) had the highest MVD compared with Japanese and older British patients (Po0.01). Japanese patients were proportionately
more likely to receive chemotherapy than endocrine therapy (Po0.01). British patients had a significantly worse relapse-free survival
and overall survival compared with Japanese patients, after statistical adjustment for variables (hazard ratio¼2.1, 2.4, Po0.01,
Po0.01, respectively), especially, in T2 stage, low MVD and older subgroup (HR: 3.6, 5.0; 3.1, 3.3; 3.2, 3.9, respectively), but only in
ER negative cases (P¼0.04, P¼0.01, respectively). The present study shows that MVD contributes to the Japanese–British disparity
in breast cancer. However, the MVD variability did not explain the survival differences between Japanese and British patients.
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There have been many reports about racial disparities in breast
cancer incidence and outcomes. Asian-American and Japanese
patients tend to have a lower incidence of breast cancer and
have a better prognosis than Caucasians (Yonemoto, 1980;
Sakamoto et al, 1981; Natarajan et al, 1988; Tominaga and
Kuroishi, 1995; Boyer-Chammard et al, 1999; Braun et al, 2004).
Age-adjusted incidence rate for breast cancer among Japanese
patients has markedly increased 1.9-fold from 1978 to 1998
(age-adjusted incidence rate: 17.9, 33.8, respectively) (The
Research Group for Population-based Cancer Registration in
Japan, 1999, 2003; Tamakoshi et al, 2005) and age-adjusted death
rate has increased moderately (Tominaga and Kuroishi, 1995),
but is still much lower compared with those of Caucasians
(Tominaga and Kuroishi, 1995; Kawamura and Sobue, 2005).
Racial differences in age-adjusted mortality rates are likely to be
due to many factors, such as genetics, diet, reproductive patterns,
socioeconomic status, geographic and environmental exposures,
and other unidentified cultural or biological factors (Iscovich et al,
1989; Claus et al, 1990; Chaudary et al, 1991; Gordon et al, 1992;
Simon and Severson, 1996; Tamakoshi et al, 2005). In spite of
numerous studies, the reason for such disparities has not been
identified.
In general, angiogenesis facilitates both tumour growth and
progression and it contributes to the aggressiveness of tumours.
Some studies have suggested that microvessel density (MVD) as a
measure of tumour angiogenesis is an independent and highly
significant prognostic factor, for both node-negative and -positive
patients (Weidner et al, 1991; Fox et al, 1995; Kato et al, 1999;
Tsutsui et al, 2003). However, the numbers of microvessels
counted by many investigators differs between studies, which also
varied in patient selection, the antibody used to detect endothelial
cells, sample size, method of counting microvessels, and race.
Since the number of microvessels reported by Western investiga-
tors appears to be higher than that by Japanese (Axelsson et al,
1995; Costello et al, 1995; Ogawa et al, 1995; Kato et al, 1999) and
green tea, consumed many times daily by the average Japanese,
inhibits vascular endothelial growth factor induction in human
breast cancer cells (Sartippour et al, 2002), we hypothesised that
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sdifferences in MVD might contribute to the Japanese and British
disparities in breast cancer outcomes.
This study was undertaken to investigate the associations of
MVD and other variables with survival, and whether they are
associated with survival differences between Japanese and British
patients.
PATIENTS AND METHODS
Two hundred and seventeen Japanese and 219 British patients were
studied, excluding patients with non-invasive, Stage IV, bilateral,
male, or inflammatory cancers, to investigate the characteristics of
primary operable invasive female breast cancer. They had under-
gone breast cancer surgery at the Tokyo Women’s Medical
University Hospital or the John Radcliffe Hospital, Oxford between
1991 and 1993. These hospitals are tertiary referral centres.
However, cases where insufficient material remained in the tissue
blocks for immunohistochemical evaluation of factor VIII-related
antigen were excluded. Eleven Japanese and 14 British samples for
study were identified retrospectively as having no carcinoma and
paraffin-embedded tissue blocks of 33 Japanese and 21 British
cases were insufficient because they have been used for other
research. This left 173 cases in the Japanese group and 184 cases in
British group for pathological analyses.
Follow-up was from medical records. Cause of death was
analysed for breast cancer alone and cases who died from other
disease was defined as censored. The date of the last note in the
medical record in Tokyo was 2000, while in Oxford it was 2001.
Oestrogen receptor (ER) content were determined biochemically
using the dextran-coated charcoal method in Tokyo and Oxford.
Tumours were classified as ER-positive if the content exceeded
5fmolmg
 1 protein. Patients’ ages were categorised as age o50
years (younger group) and age ^50 years (older group).
Pathological studies
The pathologic specimens from both hospitals were reviewed by
the same investigator (TK) without any knowledge of the eventual
clinical outcome. Conventional pathological features were ob-
served and recorded, including lymph-node status. Operative/
pathological size was used for T stage in Japanese and pathological
size for British patients. Grade was determined by the method of
Elston and Ellis grade (Elston and Ellis, 1991). Vascular invasion
was assessed on haematoxylin and eosin (H&E) sections.
Immunocytochemical techniques
Serial sections were prepared from representative formalin-fixed
and paraffin-embedded tissue blocks from this series of breast
cancers. Japanese sections were fixed in 20% formalin for 48h,
while British ones in 10% formalin for the same time. The other
processing was similar in Tokyo and Oxford. Tissue samples of
5mm thick sections stained with H&E were assessed histopatho-
logically and were used to select the maximal area of the invasive
components. Immunostains for factor VIII-related antigen were
performed on paraffin sections using the streptavidin–biotin–
immunoperoxidase method as described previously (Kato et al,
1999, 2003). Briefly, formalin-fixed, paraffin-embedded sections
were de-waxed in 100% Citroclear, rehydrated through graded
100% industrial methylated spirit series, and immunostaining was
performed using a polyclonal antibody (von Willebrand factor,
Dako, Copenhagen, Denmark) applied at 1:200 for 1h at room
temperature. Analysis of all slides of both Japanese and British
cases for H&E and factor VIII-related antigen staining was
performed by the same method and at same institute (John
Radcliffe Hospital, Headington, Oxford, UK) and both clinical and
pathological studies were done in Tokyo.
Microvessels were counted by one investigator (TK). To evaluate
the most effective method to quantify MVD in angiogenesis, two
different methods were tried. The first was average microvessel
count (AMC) per square millimetre (Kato et al, 1999, 2003). One
maximal area of all the cut surfaces exhibiting invasive compo-
nents in each tumour was scanned at high power (200 ) and the
number of microvessels in all the areas along the border between
cancer nests and the stroma was recorded (Figure 1A). The average
number of microvessels in all the fields scanned at high power was
calculated giving the mean AMC. The other method was to use the
three highest microvessel counts (HMC) per square millimetre
(Figure 1B). These criteria were similar to those of Weidner et al
(1991). The patients were divided into two groups (low or high)
according to the median AMC or HMC value (54.4, 85.3mm
 2,
respectively) of all patients.
Statistical analysis
Statistical analysis of the data was performed with the Survival
Tools for Statview-J 5.0 package (Abacus Concepts, Berkeley, CA,
USA). All tests were two-tailed. For comparison of the median
follow-up duration and the two groups and for association with
T-stage, surgical treatment, ER status, lymph-node status, grade,
vascular invasion and histologic type and the two groups,
Mann–Whitney U-test, w
2-test or Fisher’s exact tests was used.
For comparison of mean age, tumour size and MVD and the two
groups or four groups Mann–Whitney U-test or Kruskal–Wallis
test was used. We examined the univariate relationships between
prognostic indicators and relapse-free survival (RFS) and overall
survival (OS) by fitting Kaplan–Meier survival curves (Kaplan and
A
B
70 m
70 m
Figure 1 Microvessel staining: microvessels were highlighted by staining
endothelial cells (staining for factor VIII-related antigen). (A) Example of an
area from a tumour with AMC. Microvessels were highlighted by staining
endothelial cells along the border between cancer nests and stroma. (B)
Representative field of HMC showing high vascularisation.
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sMeier, 1958) to various levels of the prognostic indicators and then
looked for differences among the curves using the log–rank test
(Mantel, 1966). The Cox proportional hazards regression model
was also used for the multivariate analysis (Cox, 1972).
RESULTS
Characteristics and survival of the 436 original patient
population
Two hundred and seventeen Japanese and 219 British patients
underwent breast cancer surgery in Tokyo and Oxford. In the
original series, British patients were significantly older (56.5±11.3
years vs 52.4±12.6 years, Po0.01) and had smaller tumours
(2.1±1.6 vs 2.6±2.9cm; Po0.01) and had more ER-positive
tumours (77.2 vs 56.3%, Po0.01) compared with Japanese
patients, but there was no difference in the prevalence of lymph
node metastasis (37.9 vs 36.4%, P¼0.74). Cox regression
modelling was used to determine the effect of population and
other variables on RFS and OS. British patients had a significantly
worse RFS and OS compared with Japanese patients (P¼0.01,
P¼0.01, respectively). The adjusted hazard ratio (HR) and 95%
confidence intervals (CI) for RFS or OS for British patients
compared with Japanese patients was 2.3 (1.4–3.5) or 2.8 (1.6–4.9)
(Po0.01, Po0.01, respectively).
Characteristics of the 357 patient subset for pathological
analyses
Because of lack of tumour tissue, only a subset could be analysed
for MVD. The median follow-up duration of the Japanese and
British patients was 76 months (range, 1–105) and 90 months
Table 1 Clinicopathological characteristics of Japanese and British patients
Total Younger group Older group
Characteristics Japanese (%) British (%) P-value Japanese (%) British (%) P-value Japanese (%) British (%) P-value
Patients 173 184 79 58 94 126
Age, years
Median 51 56 43 45 60 61
Range 24–86 27–83 24–49 27–49 50–86 50–83
Mean±s.d. 52.5±12.9 56.3±11.4 o0.01 41.3±5.8 43.3±5.2 0.03 61.9±9.0 62.3±7.9 0.48
Survival follow-up, months
Median 76.3 90.4 o0.01 77.4 86.4 o0.01 76.6 92.9 o0.01
Range 1.2–105.7 6.9–135.8 2–101.8 14.2–127.2 1.2–105.7 6.9–135.8
Recurrence 32 (18.5) 63 (34.2) o0.01 18 (22.8) 22 (37.9) 0.05 14 (14.9) 41 (32.5) o0.01
Deaths 20 (11.6) 45 (24.5) o0.01 12 (15.2) 15 (25.9) 0.12 8 (8.5) 30 (23.8) o0.01
Surgical treatment o0.01 o0.01 o0.01
Radical mastectomy 149 (86.1) 33 (17.9) 70 (88.6) 11 (19.0) 79 (84.0) 22 (17.5)
Conservative surgery 24 (13.9) 151 (82.1) 9 (11.4) 47 (81.0) 15 (16.0) 104 (82.5)
Adjuvant treatment o0.01 0.02 o0.01
Chemotherapy 55 (31.8) 15 (8.2) 29 (36.7) 13 (22.4) 26 (27.7) 2 (1.6)
Chemoendocrine therapy 60 (34.7) 44 (23.9) 29 (36.7) 21 (36.2) 31 (33.0) 23 (18.3)
Endocrine therapy 21 (12.1) 114 (62.0) 8 (10.1) 17 (29.3) 14 (14.9) 97 (77.0)
None 37 (21.4) 11 (5.9) 13 (16.5) 7 (12.1) 23 (24.4) 4 (3.1)
T-stage o0.01 0.03
T1 (%2cm) 78 (45.1) 116 (63.0) 35 (44.3) 38 (65.5) 43 (45.7) 78 (61.9)
T2 (42cm and %5cm) 81 (46.8) 64 (34.8) 38 (48.1) 20 (34.5) 43 (45.7) 44 (34.9)
T3 (45cm) 14 (8.1) 4 (2.2) 6 (7.6) 0 8 (8.6) 4 (3.2)
Tumour size, cm
Median 2.2 1.9 2.2 2 2.2 1.8
Range 0.5–13.0 0.2–10.0 0.6–8.0 0.2–5.0 0.5–13.0 0.6–10.0
Mean±s.d. 2.7±1.8 2.2±1.3 o0.01 2.6±1.5 2.0±0.9 0.04 2.7±2.0 2.3±1.4 0.05
ER status o0.01 o0.01 o0.01
Negative 71 (42.8) 39 (21.2) 37 (49.3) 13 (22.4) 34 (37.4) 26 (20.6)
Positive 95 (57.2) 145 (78.8) 38 (50.7) 45 (77.6) 57 (62.6) 100 (79.4)
Unknown 7 0 4 0 3 0
Lymph-node status 0.75 0.51 0.90
Negative 105 (62.5) 112 (60.9) 50 (64.1) 34 (58.6) 55 (61.1) 78 (61.9)
Positive 63 (37.5) 72 (39.1) 28 (35.9) 24 (41.4) 35 (38.9) 48 (38.1)
Unknown 5 0 1 0 4 0
MVD
AMC
Median 50.8 57.2 51.3 64.1 50.1 64.4
Range 12.9–107.4 4.6–132.7 18.2–107.4 26.2–132.7 12.9–100.5 4.6–108.5
Mean±s.d. 53.2±18.6 57.9±19.8 0.01 53.4±19.7 64.0±21.0 52.9±17.7 55.0±18.7 o0.01
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s(range, 7–135) (Po0.01; Table 1). Clinical and pathological data
are listed in Table 1. Seven patients were lost to follow-up and one
patient died within 1 year. The other cases were followed up for
over 1 year. Japanese patients tended to be younger, with the peak
in age distribution between 40 and 49 years of age, compared to
50–59 in British patients. Mean ages were also four to five years
younger in Japanese women (means 56 and 52, Po0.01; Table 1).
Japanese patients had proportionately more T2 and T3 cases than
did the British patients (46.8, 8.1 vs 34.8, 2.2%, respectively,
Po0.01, Table 1). The ratio of ER-positive British patients was
significantly higher than that of Japanese patients (78.8 vs 57.2%,
Po0.01, Table 1). No difference in the prevalence of lymph-node
metastasis was found between Japanese and British patients (39.1
vs 37.5%, P¼0.75; Table 1). British patients had a higher AMC
compared with Japanese patients (57.9±19.8 vs 53.2±18.6;
P¼0.01), but not HMC (87.9±32.3 vs 85.1±29.9, P¼0.65,
Table 1). Moreover, younger British patients (age o50 years)
had the highest AMC compared to both younger and older
Japanese and older British patients (Po0.01, Table 1). Patients
with high AMC had proportionately more infiltrating lobular
carcinoma than did the patients with low AMC (P¼0.04).
However, there was no correlation between high AMC and
other variables such as T-stage, ER-positivity, age, lymph-node
metastasis, high grade or vascular invasion. Japanese patients
had proportionately more grade I cases than did the British
patients (46.8 vs 34.8%, P¼0.04, Table 1), however, there was no
correlation between vascular invasion and the population
(P¼0.16). There were significant differences in the surgical
treatment – for example 86.1% of Japanese patients had radical
or modified radical mastectomy vs 17.9% of British patients
(Po0.01), and conversely 13.9% of Japanese patients had
conservative surgery (local excision alone or local excision
and radiotherapy) vs 82.1% of British patients (Po0.01; Table 1).
6.5% of Japanese patients received adjuvant chemo- or chemoen-
docrine therapy vs 32.1% of British patients (Po0.01), and 12.1%
of Japanese patients had adjuvant hormone therapy alone vs 62.0%
of British patients (Po0.01). Japanese patients were proportio-
nately more likely to receive chemotherapy than endocrine
therapy.
Relationship between prognostic variables and relapse-free
survival (RFS) and overall survival (OS)
British patients had a significantly worse RFS and OS compared
with Japanese patients (P¼0.01, P¼0.02, respectively; Figures 2A
and B). For patients in T2 stage subgroup, British patients had a
significantly worse RFS and OS than Japanese patients (Po0.01,
Po0.01, respectively; Figures 3A and B). Also for patients in the T3
stage subgroup, British patients had a significantly worse RFS
compared with Japanese patients (P¼0.04), but not a worse OS
(P¼0.12; curves not shown). But for patients in T1 subgroup there
was no difference (P¼0.19, P¼0.17, respectively; curves not
shown). For breast cancer stratified by ER status, ER-negative
British patients had a worse OS than Japanese patients (P¼0.04;
curves not shown), but not a worse RFS (P¼0.10). In contrast,
there was no significant difference in RFS and OS amongst
Japanese and British women with ER-positive cases (P¼0.14,
P¼0.27, respectively; curves not shown). For patients in the older
subgroup, British patients had a significantly worse RFS and OS
than Japanese patients (P¼0.03, P¼0.02, respectively;Figures 4A
and B) but not for patients in younger subgroup (P¼0.15,
P¼0.50, respectively; curves not shown). Moreover, RFS and OS
for ER-negative British older patients was worse than for Japanese
(P¼0.04, P¼0.01, respectively; Figures 4C and D), while there was
no significant difference in RFS and OS amongst ER-positive
Japanese and British older women (P¼0.24, P¼0.29, respectively;
curves not shown).
Univariate and multivariate analyses of relapse-free
survival (RFS) and overall survival (OS)
Model 1 of Table 2 indicates that British patients had a
significantly worse RFS and OS compared with Japanese patients
(HR: 2.1, 2.4, Po0.01, Po0.01, respectively) and patients with T2
or T3-stage and grade III had a significantly worse RFS and OS
compared with the patients with T1-stage and grade I. However,
AMC was not associated with RFS and OS in either analyses.
British patients also had a significantly worse RFS and OS
compared with Japanese patients in the model 2 (HR: 2.6, 3.2;
Table 1 (Continued)
Total Younger group Older group
Characteristics Japanese (%) British (%) P-value Japanese (%) British (%) P-value Japanese (%) British (%) P-value
HMC
Median 86.7 84.7 89.0 92.2 84.1 81.2
Range 20.9–153.8 20.8–266.0 20.9–147.4 50.3–171.7 23.4–153.8 20.8–266.0
Mean±s.d. 85.1±29.9 87.9±32.3 0.65 86.2±30.8 96.6±30.0 84.1±29.2 83.9±32.6 0.08
Grade 0.04 0.16 0.26
I 81 (46.8) 64 (34.8) 37 (46.8) 18 (31.0) 44 (46.8) 46 (36.5)
II 55 (31.8) 65 (35.3) 27 (34.2) 24 (41.4) 28 (29.8) 41 (32.5)
III 37 (21.4) 55 (29.9) 15 (19.0) 16 (27.6) 22 (23.4) 39 (31.0)
Vascular invasion 0.16 0.54 0.26
Negative 114 (65.9) 125 (67.9) 45 (57.0) 36 (62.1) 69 (73.4) 89 (70.6)
Positive 59 (34.1) 59 (32.1) 34 (43.0) 22 (37.9) 25 (26.6) 37 (29.4)
Histologic type o0.01 0.20 0.14
Infiltrating ductal carcinoma 154 (89.0) 152 (82.6) 72 (91.1) 49 (84.5) 82 (87.2) 103 (81.7)
Infiltrating lobular carcinoma 7 (4.0) 25 (13.6) 1 (1.3) 7 (12.1) 6 (6.4) 18 (14.3)
Others 12 (7.0) 7 (3.8) 6 (7.6) 2 (3.4) 6 (6.4) 5 (4.0)
Younger group: age o50 years; Older group: age ^50 years. ER¼oestrogen receptor; MVD¼microvessel density; AMC¼average microvessel counts; HMC¼highest
microvessel counts. Younger group: age o50 years; Older group: age ^50 years. Per cent do not include cases of unknown ER or lymph-node status.
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sPo0.01, Po0.01, respectively). In particular, British patients with
T2 tumours had significantly worse RFS and OS compared with
Japanese women (HR: 3.6, 5.0; Po0.01, Po0.01, respectively;
Table 3). In the T-2 stage subgroup, lymph-node status was
significantly associated with RFS and OS (HR: 2.4, 2.1; Po0.01,
P¼0.03, respectively; Table 3). Table 4 shows the unadjusted
hazard ratio for age and population with multivariate adjusted
hazard ratio being controlled for T-stage, nodes status, ER status,
grade, AMC, and vascular invasion. The unadjusted hazard ratio
for RFS or OS for older British patients compared with older
Japanese patients was 1.9 or 2.4 (P¼0.03, P¼0.03, respectively,
Table 4). After controlling for other variables, the hazard ratio of
RFS or OS for them was 3.2 or 3.9 (Po0.01, Po0.01, respectively,
Table 4). Older Japanese patients had better outcomes than older
Japanese (n = 81)
British (n = 64)
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Figure 3 Kaplan–Meier survival curves for all patients with T2 tumours. (A) Relapse-free survival for the patients with T2 tumours stratified by
population. (B) Overall survival for the patients with T2 tumours related to population.
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Figure 2 Kaplan–Meier survival curves for all patients with breast cancer. (A) Relapse-free survival stratified by population. (B) Overall survival related to
population.
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Figure 4 Kaplan–Meier survival curves for older patients with breast cancer. (A) Relapse-free survival l for all older patients stratified by population. (B)
Overall survival for all older patients related to population. (C) Relapse-free survival l for ER-negative older patients stratified by population. (D) Overall
survival for ER-negative older patients related to population.
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sBritish patients, while there were no significant differences among
younger Japanese and British patients. In the low AMC subgroup,
the population and T-stag were significantly associated with RFS
and OS in multivariate analysis (model 1 of Table 5). In contrast, in
the high AMC subgroup, although T-stage, lymph-node status and
grade significantly affected the association with RFS and OS,
population had no effect on RFS and OS (model 2 of Table 5).
DISCUSSION
Several investigators have found that Japanese patients with breast
cancer have a better survival than American or British patients
(Wynder et al, 1963; Morrison et al, 1976; Friedel et al, 1991).
There are several limitations to these hospital-based studies. There
is often insufficient uniformity amongst populations. There might
have been a selection bias. In the previous studies, none used
multivariate methods to simultaneously control the other prog-
nostic variables. Thus, it is not known whether these survival
differences were due to race or tumour variables. Our results,
however, do show the better outcome in older Japanese compared
with older British patients before and after adjusting for other
variables (Table 4). Only other study showed that the difference in
survival was restricted to postmenopausal patients (Sakamoto
et al, 1981). Age-adjusted mortality rates in England and Wales
started to decrease in the late 1980s (Beral et al, 1995), while those
in Japan have gradually increased, but still lower than the former
rates (Tominaga and Kuroishi, 1995; The Research Group for
Population-based Cancer Registration in Japan, 2003) As there has
been a gradual improvement in survival in British patients, the
magnitude of survival differences reported in this study was not
nearly as great as that reported in a previous study (Merchant et al,
1999). Improved survival from this cancer in the UK may be due to
increased social interest, advances in diagnosis according to the
NHS Breast Screening Programme, and development of adjuvant
endocrine therapy and chemotherapy (Beral et al, 1995; Kobayashi,
2004).
There is also strong evidence to suggest a population-dependent
variation in the biology of breast cancer, such as ER status, p53
gene mutation, HER-2/neu, S-phase fraction, lymphatic infiltra-
tion, sinus histiocytosis, and certain histological patterns (Sakamoto
et al, 1981; Friedel et al, 1991; Elledge et al, 1994; Merchant et al,
1999). Differences in these biologic characteristics do not explain
the relatively high survival rate of Japanese breast cancer patients.
According to the study of Braun et al (2004), native Hawaiian
patients had a poor survival in spite of a high ER positivity rate.
The current study also showed that British patients had a high
percentage of ER-positive tumours and an increased risk of death,
in spite of the extensive use of adjuvant endocrine therapy. In our
study the pathological variables do not explain why the survival of
Table 2 Multivariate analysis of the value of prognostic factors for relapse-free survival and overall survival among all Japanese and British patients
Model
Model 1 Model 2
Relapse-free survival Overall survival Relapse-free survival Overall survival
Variable HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
Population
British vs Japanese 2.1 1.3–3.6 o0.01 2.4 1.3–4.4 o0.01 2.6 1.4–4.9 o0.01 3.2 1.6–6.6 o0.01
Age group
Younger vs older 1.3 0.9–2.1 0.16 1.3 0.8–2.1 0.33 1.2 0.8–1.9 0.41 1.1 0.7–1.9 0.65
T-stage
T2 vs T1 2.5 1.6–4.0 o0.01 2.8 1.6–4.9 o0.01
T3 vs T1 4.6 1.9–11.1 o0.01 7.1 2.8–18.0 o0.01
Lymph-node status
Positive vs negative 2.4 1.6–3.7 o0.01 2.5 1.5–4.1 o0.01
ER status
Negative vs positive 1.1 0.7–1.8 0.73 1.2 0.7–2.1 0.56
Grade
II vs I 1.9 1.1–3.2 0.01 1.9 1.0–3.6 0.05
III vs I 1.9 1.1–3.5 0.03 2.2 1.1–4.5 0.02
AMC
High vs low 0.9 0.6–1.4 0.58 1.0 0.6–1.7 0.98 0.8 0.6–1.3 0.41 0.9 0.6–1.5 0.78
Vascular invasion
Positive vs negative 0.9 0.6–1.3 0.48 0.8 0.5–1.4 0.47 1.1 0.8–1.8 0.51 1.1 0.7–1.9 0.63
Surgical treatment
Mastectomy vs conservative 0.6 0.3–1.0 0.05 0.5 0.3–0.9 0.01
Adjuvant tratment
Chemo alone vs None 2.7 0.9–8.1 0.06 1.5 0.5–4.7 0.50
Chemoendocrine vs None 3.0 1.1–8.4 0.03 1.8 0.6–5.2 0.28
Endocrine alone vs None 1.9 0.6–5.4 0.25 1.2 0.4–3.5 0.80
AMC¼average microvessel counts; ER¼estrogen receptor; HR¼hazards ratio; 95% CI¼ 95% confidence interval. Younger group: age o50 years; Older group: age ^50
years Multivariate model 1 adjusted for population, age, T-stage, lymph-node status, ER status, grade, AMC and vascular invasion. Multivariate model 2 adjusted for population,
age, AMC, vascular invasion, surgical treatment and adjuvant treatment. Hazards ratio from Cox regression analysis.
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sBritish patients is poorer than Japanese patients, as the former had
smaller and more ER-positive tumours than the latter and the
prevalence of lymph-node involvement was also the same.
Therefore, we investigated MVD as a possible mechanism, because
the Japanese diet is rich in antioxidants and green tea, consumed
many times daily by the average Japanese and contains active
antiangiogenic substances (Sartippour et al, 2002; Rodriguez et al,
2006). Thus, dietary differences involving these agents was a
possible factor.
To our knowledge, this is the first study to compare the
prognostic value of microvessel density in Japanese and British
patients with invasive breast cancer. Various techniques for the
evaluation of neovascularisation have been tested in breast cancer.
Some studies have suggested that microvessel density was
representative of angiogenesis of the tumour and was an
independent and highly significant prognostic factor (Weidner
et al, 1991; Horak et al, 1992; Gasparini et al, 1994; Kato et al, 2001;
Tsutsui et al, 2003). However, other authors reported that
angiogenesis did not predict recurrence in patients with primary
breast cancer (van Hoef et al, 1993; Goulding et al, 1995). The
significance of angiogenesis remains controversial due to studies
which varied in patient selection, length of time of patient follow-
up, antibody used to detect endothelial cells, sample size, method
of counting microvessels, and the race. Some clinical studies
suggested that to use an antibody to CD31 may be superior to
using factor VIII-related antigen (Horak et al, 1992; Fox et al,
1995); however, another study reported that this greater sensitivity
of anti-CD31 of vascular endothelium did not yield results more
discriminating for predicting survival outcome than results
produced with factor VIII-related antigen (Gasparini et al, 1994).
Using an antibody to the latter antigen, many stromal vessels can
be stained well as we published previously (Kato et al, 1999). When
we compared AMC with the highest microvessel density in one or
three fields (the hot spots) in the previous study, AMC was a more
reliable factor than that of the hot spots (Kato et al, 1999). The
results show that AMC was an independent prognostic factor, but
its prognostic impact was not as strong as lymph-node status and
clinical tumour size. The method of Weidner et al (1991) is
popular , however, we have questioned whether or not the hot
spots in one slide per tumour is representative for the whole
tumour. Selection of the hot-spots area for counting is one of the
possible sources of this discordance and it requires the judgment
of the investigators to select which region is the most vascular
(Kato et al, 1999, 2003; Medri et al, 2000). Both the Chalkley
method and computerised imaging analysis may reduce the
subjectivity of evaluation in quantification of microvessel count
(Fox et al, 1995; Gasparini, 2001; Hansen et al, 2004). In a prior
study, Kato et al (1999) showed that the area of highest
microvessels most frequently (76.5%) appeared at the margins of
the carcinoma, where invasion is taking place and active growth
most likely and they counted the number of the microvessels along
Table 3 Multivariate analysis of the value of prognostic factors for
relapse-free survival and overall survival among Japanese and British patients
with T2 tumours
Relapse-free survival Overall survival
Variable HR 95% CI P-value HR 95% CI P-value
Population
British vs Japanese 3.6 1.9–6.9 o0.01 5.0 2.1–11.8 o0.01
Age group
Younger vs older 1.1 0.6–1.9 0.82 1.1 0.5–2.2 0.81
Lymph-node status
Positive vs negative 2.4 1.4–4.3 o0.01 2.1 1.1–4.1 0.03
ER status
Negative vs positive 1.6 0.8–3.1 0.20 2.0 0.9–4.6 0.08
Grade
II vs I 1.7 0.6–3.5 0.14 1.6 0.6–4.0 0.30
III vs I 1.2 0.5–2.8 0.65 1.5 0.6–4.1 0.42
AMC
High vs low 0.7 0.4–1.3 0.24 0.8 0.4–1.6 0.45
Vascular invasion
Positive vs negative 1.1 0.6–1.9 0.78 1.0 0.5–2.0 0.98
AMC¼average microvessel counts; ER¼oestrogen receptor; HR¼hazards ratio;
95% CI¼ 95% confidence interval. Younger group: age o50 years; Older group: age
^50 years. Multivariate models adjusted for population, age, lymph-node status, ER
status, grade, AMC and vascular invasion. Hazards ratio from Cox regression analysis.
Table 4 Age-specific models among British patients compared with Japanese patients
Relapse-free survival Overall survival
Variable HR 95% CI P-value HR 95% CI P-value
Older group (Age ^50 years)
Unadjusted
Population (British vs Japanese) 1.9 1.1–3.6 0.03 2.4 1.1–5.2 0.03
AMC (high vs low) 1.2 0.7–2.1 0.41 1.4 0.7–2.7 0.27
Multivariate adjusted
Population (British vs Japanese) 3.2 1.6–6.3 o0.01 3.9 1.7–8.9 o0.01
AMC (high vs low) 1.3 0.7–2.3 0.35 1.3 0.7–2.5 0.46
Younger group (Age o50 years)
Unadjusted
Population (British vs Japanese) 1.6 0.8–2.9 0.15 1.4 0.6–3.1 0.35
AMC (high vs low) 0.6 0.3–1.1 0.12 0.8 0.4–1.7 0.53
Multivariate adjusted
Population (British vs Japanese) 1.5 0.7–3.2 0.29 1.1 0.4–2.8 0.86
AMC (high vs low) 0.6 0.3–1.1 0.09 0.9 0.4–2.0 0.78
AMC¼average microvessel counts; ER¼oestrogen receptor; HR¼hazards ratio; 95% CI¼ 95% confidence interval. Multivariate models adjusted for population, T-stage,
lymph-node status, ER status, grade, AMC and vascular invasion. Hazards ratio from Cox regression analysis.
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sthe border between cancer nests and the stroma (Figure 1A). The
average number of microvessels in all the fields scanned at high
power was calculated giving the mean AMC. We think that the
method of determining AMC might be a more objective method
than that of the hot spots because if the edge of the tumour for
counting is decided, it is not so difficult to count the vessels,
although it was somewhat subjective to determine the edge of the
tumour with either ductal carcinoma in situ or lobular carcinoma
in situ for counting. Thus, the significance of the methods for
evaluation of microvessels remains controversial.
In the current study, to investigate the associations of
microvessel density and other variables with survival, and whether
they correlate with survival differences between Japanese and
British patients, we used the methods of both Weidner et al (1991)
and Kato et al (1999) between Japanese and British patients.
British patients had a higher AMC compared with Japanese
patients, but not HMC. In particular, younger British patients had
the highest AMC of the 4 groups. AMC appears to be a more useful
surrogate marker of tumour angiogenesis than HMC in this series.
AMC and HMC were used as continuous variables at first to
investigate the associations of microvessel density and other
variables with survival. They were also divided into either two or
three categories to analyse, but this did not significantly change the
lack of association with survival. Population was significantly
associated with RFS and OS in the low AMC subgroup, but had no
effect on RFS and OS in high AMC subgroup. T-stage, lymph-node
status and grade significantly affected the association with RFS and
OS in the latter subgroup. Thus, there was no Japanese–British
disparity in the more aggressive breast tumours with high AMC,
tumours more than 2cm, positive nodes or high grade. The present
study shows that AMC contributes to the Japanese–British
disparity in breast cancer. However, this study does not explain
the favourable prognosis for Japanese patients, especially, for those
who are older.
The administration of systemic adjuvant chemotherapy or
endocrine therapy can improve RFS and OS in breast cancer
patients (Early Breast Cancer Trialist’ Collaborative Group, 1992).
ER status is used to inform breast cancer treatment, and patients
with ER-positive tumours are candidates for tamoxifen or similar
agents. In contrast, patients with ER-negative tumours are often
given chemotherapy. Boyer-Chammard et al (1999) reported that
African-American, Hispanic, and Asian patients with breast cancer
from 1984 through 1990 were more likely than Caucasian patients
to receive chemotherapy and less likely to receive endocrine
therapy. The current study is similar to those results. The study by
the Collaborative Study Group of Adjuvant Chemoendocrine
Therapy for Breast Cancer (ACETBC) in Japan was carried out
from 1982 (Kasumi et al, 2003; Noguchi et al, 2005). Most of the
Japanese patients in this study were treated according to that
regimen. As Japanese patients had more ER-negative tumours than
British patients, they were more likely to receive chemotherapy
than endocrine therapy. Treatment may be a contributing factor
on survival between populations. There were clear differences in
the treatment policies. After controlling for population, age, AMC
and vascular invasion, surgical treatment affected the association
with the survival, but adjuvant treatment had no effect on the
survival (Table 2). However, patients who received chemotherapy
alone had significantly better prognosis than those who had no
adjuvant therapy in ER-negative subgroup alone (RR: 0.1, 95% CI:
0.02–0.8, P¼0.03).
There are several limitations to the current study. Firstly, it is
not certain that the cases are comparably representative of the
population cases in each country and there might have been a
selection bias. However the patients came from the population
local to their main cancer centres. Secondly, medical care
procedures and patterns differ significantly in each country.
Thirdly, there is the possibility that any systemic differences in the
handling of tissue may well affect the immunohistochemical
results. Fourthly, as the number of the cases we studied is less than
the original selected Japanese and British cases, there may be some
bias, but distribution of age, tumour size, ER status and survival in
the original cases was similar to those of the cases in the pathology
Table 5 Multivariate analysis of the value of prognostic factors for relapse-free survival and overall survival among Japanese and British patients with low
and high AMC tumours
Model
Model 1 (low AMC) Model 2 (high AMC)
Relapse-free survival Overall survival Relapse-free survival Overall survival
Variable HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
Population
British vs Japanese 3.1 1.5–6.4 o0.01 3.3 1.3–8.2 o0.01 1.7 0.8–3.4 0.14 1.7 0.8–3.9 0.19
Age group
Younger vs older 2.3 1.2–4.3 o0.01 1.9 0.9–3.9 0.09 1.0 0.6–1.9 0.91 1.2 0.6–2.4 0.68
T-stage
T2 vs T1 3.0 1.5–5.8 o0.01 3.9 1.7–8.8 o0.01 2.5 1.3–4.8 o0.01 2.5 1.1–5.4 0.02
T3 vs T1 1.7 0.3–8.2 0.49 3.9 0.7–20.2 0.10 22.1 6.4–76.4 o0.01 15.3 4.3–54.7 o0.01
Lymph-node status
Positive vs negative 2.5 1.4–4.4 o0.01 1.9 0.9–4.0 0.06 2.1 1.1–3.9 0.02 2.9 1.3–6.3 o0.01
ER status
Negative vs positive 1.0 0.5–1.9 0.95 1.0 0.5–2.4 0.91 1.5 0.7–3.1 0.26 1.8 0.8–4.2 0.17
Grade
II vs I 1.5 0.7–3.1 0.25 1.4 0.6–3.3 0.48 2.8 1.3–6.2 0.01 3.1 1.2–8.4 0.02
III vs I 1.5 0.6–3.4 0.36 1.5 0.6–4.0 0.38 3.9 1.6–9.4 o0.01 4.2 1.4–12.9 0.01
Vascular invasion
Positive vs negative 1.1 0.6–1.9 0.78 0.9 0.4–1.9 0.73 0.6 0.3–1.2 0.12 0.8 0.3–1.7 0.49
HR¼hazards ratio; 95%CI¼95% confidence interval. ER¼oestrogen receptor; AMC¼average microvessel counts. Younger group: age o50 years; Older group: age ^50
years. Multivariate models adjusted for population, age, T-stage, lymph-node status, ER status, grade and vascular invasion. Hazards ratio from Cox regression analysis.
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sanalysis. Finally, the length of time of follow-up varied according
to the two groups, but this would not affect the survival curves for
first 5 years. The advantage of this study includes consistency in
the antibody used to detect endothelial cells and the methods of
counting microvessels, that is same polyclonal antibody for factor
VIII-related antigen was used. All slides of both Japanese and
British patients for H&E and factor VIII-related antigen staining
were performed according to the same method and at the same
institute (John Radcliffe Hospital, Headington, Oxford, UK).
Overall therefore this study shows the difference between
populations occurs in the older age group, not younger, and in
the population with low AMC. Although younger British patients
had the highest AMC, their prognosis was not worse than the
Japanese younger patients. In the smallest tumours again there was
no population difference in survival, only in the T2 stage tumours
was this seen. For those with ER-positive tumours there was no
difference in relapse-free or overall survival and numbers are small
with this subgroup analysis. However it appears that ER-negative
British patients had much worse survival than ER-negative
Japanese patients. The relation to ER suggest that the growth-
stimulating pathways for ER-negative cases may be different in
the two populations perhaps modified by diet. Also since the
difference applied to ER-negative patients, the much greater use of
chemotherapy may have helped improve outcome. It will be
interesting to compare a more recent series from within the last 5
years, to see if this difference has been reduced due to much
greater use of chemotherapy currently in this group, ER negative
over 50s, in the UK.
These findings suggest that a haematogenous pattern of
dissemination may be more important than a lymphatic one for
international disparities in breast cancer outcomes. It can be
speculated that the other surrogate markers of tumour angiogenesis
or other biological variables for haematogenous dissemination
or the growth pathways in relation to ER-negative status
contribute to the worse survival of British patients. Further
research into the biological behaviour of international differences
and their effect on the survival of patients with breast cancer
should be continued.
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